mesoestetic Pharma Group
David M. has extensive work experience in operations and production management roles. David most recently held the position of Operations Director (COO) at mesoestetic Pharma Group, where they oversaw supply chain operations and managed suppliers. Prior to that, they worked as the Production and Process Engineering Director / Industrial Operations Manager at Recipharm, where they were responsible for managing manufacturing, process engineering, and maintenance. Before joining Recipharm, David served as the Deputy Operations and Production Manager at BCN Peptides and as the Production and Environmental Protection Department Manager at Interquim, S.A. - Grupo Ferrer Internacional.
David M. has a diverse education history. Starting in 1990, they attended the Universitat de Barcelona, where they obtained a Bachelor of Science degree in Organic Chemistry in 1995. Following this, from 1995 to 1997, David pursued a Master's degree in Biotechnology at CSIC - UB. Moving forward, in 2002, they attended the Universitat Politècnica de Catalunya for an additional Master's degree, focused on Operations Management and Production Organization (ENGIPLANT). Lastly, in 2008, David completed their education at EUNCET, where they earned an MBA in Business Administration.
This person is not in any offices
mesoestetic Pharma Group
mesoestetic Pharma Group is a pharmaceutical laboratory internationally recognized as one of the leaders in the field of dermatology and aesthetic medicine offering innovative and efficient solutions for skin treatment and care. The company manufactures cosmeceutical, nutraceuticals, class III intradermal administration medical devices with CE conformity marking, topical drugs as well as energy based medical aesthetic devices. This full range of integral aesthetic solutions is characterized by a high degree of innovation and significant scientific contribution. Since its inception in 1984, the firm has been committed to meeting strict pharmaceutical standards and complying with the most stringent European regulations. The company facilities are authorized by the Spanish Agency for Medicines and Medical Devices (AEMYPS) and include three pharmaceutical manufacturing lines (cosmeceuticals and nutraceuticals / intradermal administration medical devices / injectable and topical drugs), as well as a Biotechnology Unit and a Monitoring and Follow-Up Unit. These units enable the company to cover the entire production cycle and carry out in vitro and in vivo studies to ensure the safety and efficacy of its products.